search
Back to results

Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis

Primary Purpose

Primary Biliary Cirrhosis

Status
Completed
Phase
Not Applicable
Locations
Kazakhstan
Study Type
Interventional
Intervention
Sublimated mare milk
Ursodeoxycholic Acid
Sponsored by
National Scientific Medical Center, Kazakhstan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Biliary Cirrhosis focused on measuring Primary Biliary Cirrhosis, Primary Biliary Cholangitis, Mare Milk

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with morphologically verified diagnosis of primary biliary cholangitis
  • Aged 18 to 75 years
  • Willingness to consent to participate in the study
  • Consent to adhere to treatment

Exclusion Criteria:

  • Alcohol and/or drug dependence
  • Presence of liver cirrhosis class C based on Child Pugh classification
  • Allergic reaction to dairy products
  • Presence of mental diseases, severe concomitant pathology
  • Pregnancy and/or lactation
  • Lactose intolerance
  • Refusal to participate in the study

Sites / Locations

  • National Research Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Dietary supplement and ursodeoxycholic acid therapy.

Ursodeoxycholic acid therapy only.

Arm Description

Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.

Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.

Outcomes

Primary Outcome Measures

Biochemical changes in liver function.
Levels of alanine aminotransferase and aspartate aminotransferase will be measured from a biochemical blood test.
Change in intensity of asthenia in patients.
Intensity of asthenia will be assessed with the State-Asthenic Scale by L. Malkova (adapted by Chertova) with scores less than 50 and more than 100 indicating no asthenia and pronounced asthenia respectively.
Evaluation of liver histology.
Liver histology, histochemistry, immunohistochemistry will be evaluated based on biopsy samples.
Change from baseline in hepatic encephalopathy indicator.
Presence and stage of hepatic encephalopathy will be determined using the Reitan test (number connection test)

Secondary Outcome Measures

Change in inflammatory biomaker (erythrocyte sedimentation rate).
The erythrocyte sedimentation rate will be measured using the Panchenkov method
Determination of cholestasis presence/stage.
Cholestasis will be assessed according to levels of gamma-glutamyltransferase, Alkaline phosphatase, direct bilirubin, total bilirubin from blood samples.
Evaluation of changes in synthetic function of liver (prothrombin time).
Synthetic function of liver will be evaluated from the blood test result of prothrombin time.
Evaluation of changes in synthetic function of liver (fibrinogen).
Synthetic function of liver will be evaluated from blood test results of fibrinogen, and platelet count.
Evaluation of changes in synthetic function of liver (albumin).
Synthetic function of liver will be evaluated from blood test results of albumin.
Evaluation of changes in low-density lipoprotein.
Synthetic function of liver will be evaluated from blood test results of low-density lipoprotein.
Evaluation of changes in total protein.
Synthetic function of liver will be evaluated from blood test results of total protein.
Evaluation of changes in platelet count.
Synthetic function of liver will be evaluated blood test results of platelet count.
Detection of anemia.
Blood hemoglobin level will be used as a parameter for diagnosing anemia.
Hepatic hypertension
Detection of hepatic hypertension will be carried out via platelet level assessment from the blood samples.

Full Information

First Posted
September 6, 2018
Last Updated
January 23, 2021
Sponsor
National Scientific Medical Center, Kazakhstan
Collaborators
Eurasia Invest Ltd., Ministry of Education and Science, Republic of Kazakhstan
search

1. Study Identification

Unique Protocol Identification Number
NCT03665519
Brief Title
Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis
Official Title
Clinical Trial on the Effect of Sublimated Mare Milk Supplement in Patients With Biliary Cholangitis
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 3, 2018 (Actual)
Primary Completion Date
September 1, 2020 (Actual)
Study Completion Date
December 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Scientific Medical Center, Kazakhstan
Collaborators
Eurasia Invest Ltd., Ministry of Education and Science, Republic of Kazakhstan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the effect of sublimated mare milk supplement on patients with biliary cholangitis
Detailed Description
Primary biliary cholangitis, formerly known as primary biliary cirrhosis, is a rare chronic disease that primarily affects women. Primary biliary cholangitis often progresses to the terminal stage of liver cirrhosis with its inherent complications. At this stage, the only way to save the patient's life is liver transplantation, and is accompanied by a number of painful symptoms (itching, mucous dryness, abdominal discomfort, fatigue), often restless legs syndrome, insomnia, depression and cognitive dysfunction. The goal of the treatment is to prevent the terminal stage of cirrhosis of the liver and to alleviate the accompanying symptoms. Conventional drug therapy is aimed at slowing the progression of the disease and includes both approved for the use of these medications (ursodeoxycholic acid) and used outside the approved indications (derivatives of fibric acid, budesonide). The role of this clinical trial is to increase the effectiveness of therapy for this disease. Against the background of the complexity of the treatment of primary biliary cholangitis, clinical medicine acquires a remedy in the form of a natural product - mare's milk, preventive, dietary, medicinal effects of which have been known for a long time. There are data from studies that have shown the efficacy and safety of using mare milk in patients with atopic dermatitis as well as with inflammatory bowel diseases. For the liver diseases, there are no reported studies. In this trial, there will be two parallel groups: Interventional (supplement with standard treatment first for 3 months) and Standard treatment group. Differences in clinical, laboratory, liver encephalopathy and asthenia will be evaluated between groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Biliary Cirrhosis
Keywords
Primary Biliary Cirrhosis, Primary Biliary Cholangitis, Mare Milk

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dietary supplement and ursodeoxycholic acid therapy.
Arm Type
Experimental
Arm Description
Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
Arm Title
Ursodeoxycholic acid therapy only.
Arm Type
Other
Arm Description
Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
Sublimated mare milk
Intervention Description
The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
Intervention Type
Drug
Intervention Name(s)
Ursodeoxycholic Acid
Intervention Description
Ursodeoxycholic acid treatment will be given for 3 months.
Primary Outcome Measure Information:
Title
Biochemical changes in liver function.
Description
Levels of alanine aminotransferase and aspartate aminotransferase will be measured from a biochemical blood test.
Time Frame
Baseline, Month 4
Title
Change in intensity of asthenia in patients.
Description
Intensity of asthenia will be assessed with the State-Asthenic Scale by L. Malkova (adapted by Chertova) with scores less than 50 and more than 100 indicating no asthenia and pronounced asthenia respectively.
Time Frame
Baseline, Month 4
Title
Evaluation of liver histology.
Description
Liver histology, histochemistry, immunohistochemistry will be evaluated based on biopsy samples.
Time Frame
Month 4
Title
Change from baseline in hepatic encephalopathy indicator.
Description
Presence and stage of hepatic encephalopathy will be determined using the Reitan test (number connection test)
Time Frame
Baseline, Month 4
Secondary Outcome Measure Information:
Title
Change in inflammatory biomaker (erythrocyte sedimentation rate).
Description
The erythrocyte sedimentation rate will be measured using the Panchenkov method
Time Frame
Baseline, Month 4
Title
Determination of cholestasis presence/stage.
Description
Cholestasis will be assessed according to levels of gamma-glutamyltransferase, Alkaline phosphatase, direct bilirubin, total bilirubin from blood samples.
Time Frame
Baseline, Month 4
Title
Evaluation of changes in synthetic function of liver (prothrombin time).
Description
Synthetic function of liver will be evaluated from the blood test result of prothrombin time.
Time Frame
Baseline, Month 4
Title
Evaluation of changes in synthetic function of liver (fibrinogen).
Description
Synthetic function of liver will be evaluated from blood test results of fibrinogen, and platelet count.
Time Frame
Baseline, Month 4
Title
Evaluation of changes in synthetic function of liver (albumin).
Description
Synthetic function of liver will be evaluated from blood test results of albumin.
Time Frame
Baseline, Month 4
Title
Evaluation of changes in low-density lipoprotein.
Description
Synthetic function of liver will be evaluated from blood test results of low-density lipoprotein.
Time Frame
Baseline, Month 4
Title
Evaluation of changes in total protein.
Description
Synthetic function of liver will be evaluated from blood test results of total protein.
Time Frame
Baseline, Month 4
Title
Evaluation of changes in platelet count.
Description
Synthetic function of liver will be evaluated blood test results of platelet count.
Time Frame
Baseline, Month 4
Title
Detection of anemia.
Description
Blood hemoglobin level will be used as a parameter for diagnosing anemia.
Time Frame
Baseline, Month 4
Title
Hepatic hypertension
Description
Detection of hepatic hypertension will be carried out via platelet level assessment from the blood samples.
Time Frame
Baseline, Month 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with morphologically verified diagnosis of primary biliary cholangitis Aged 18 to 75 years Willingness to consent to participate in the study Consent to adhere to treatment Exclusion Criteria: Alcohol and/or drug dependence Presence of liver cirrhosis class C based on Child Pugh classification Allergic reaction to dairy products Presence of mental diseases, severe concomitant pathology Pregnancy and/or lactation Lactose intolerance Refusal to participate in the study
Facility Information:
Facility Name
National Research Medical Center
City
Astana
ZIP/Postal Code
010000
Country
Kazakhstan

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19462320
Citation
Foekel C, Schubert R, Kaatz M, Schmidt I, Bauer A, Hipler UC, Vogelsang H, Rabe K, Jahreis G. Dietetic effects of oral intervention with mare's milk on the Severity Scoring of Atopic Dermatitis, on faecal microbiota and on immunological parameters in patients with atopic dermatitis. Int J Food Sci Nutr. 2009;60 Suppl 7:41-52. doi: 10.1080/09637480802249082. Epub 2009 May 21.
Results Reference
background
PubMed Identifier
26656278
Citation
Guri A, Paligot M, Crevecoeur S, Piedboeuf B, Claes J, Daube G, Corredig M, Griffiths MW, Delcenserie V. In vitro screening of mare's milk antimicrobial effect and antiproliverative activity. FEMS Microbiol Lett. 2016 Jan;363(2):fnv234. doi: 10.1093/femsle/fnv234. Epub 2015 Dec 9.
Results Reference
background
PubMed Identifier
10392421
Citation
Valiev AG, Valieva TA, Valeeva GR, Speranskii VV, Levachev MM. [The effect of the essential fatty acids in mare's milk on the function of the immune system and of nonspecific resistance in rats]. Vopr Pitan. 1999;68(3):3-6. Russian.
Results Reference
background
PubMed Identifier
23035710
Citation
Wulijideligen, Asahina T, Hara K, Arakawa K, Nakano H, Miyamoto T. Production of bacteriocin by Leuconostoc mesenteroides 406 isolated from Mongolian fermented mare's milk, airag. Anim Sci J. 2012 Oct;83(10):704-11. doi: 10.1111/j.1740-0929.2012.01010.x. Epub 2012 Mar 13.
Results Reference
background
Links:
URL
https://clinicaltrials.gov/ct2/show/NCT00940576
Description
Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases

Learn more about this trial

Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis

We'll reach out to this number within 24 hrs